홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
Heatmap
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
IMTX
#2196
Immatics N.V. Ordinary Shares
10.950
0
USD
+0.74%
부문:
헬스케어
베이스:
USD
수익 통화:
USD
일일 변동 비율
년간 변동
일일 변동
+0.74%
월간 변동
+16.00%
6달 변화
+5.80%
년간 변동율
+5.80%
이전 종가
10.870
0
Open
10.950
0
Bid
Ask
Low
10.950
0
High
10.950
0
양
19
마켓
주식
헬스케어
IMTX
Open full chart
Financials
Overview
성명
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
62.91 M
62.93 M
76.67 M
84.66 M
121.55 M
134.07 M
416.95 M
Valuation ratios
Enterprise value
678.78 M
845.74 M
657.07 M
907.53 M
864.22 M
1.41 B
3.84 B
Price to earnings ratio
—
—
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
—
—
Price to book ratio
—
—
—
—
—
—
—
EBITDA 비율에 대한 기업 가치
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
—
—
—
—
—
—
—
Return on equity %
—
—
—
—
—
—
—
Return on invested capital %
—
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
—
—
—
—
—
—
—
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
—
—
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
—
—
Working capital per share
—
—
—
—
—
—
—
Book value per share
—
—
—
—
—
—
—
뉴스
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX)
Immatics NV Q1 실적, 수익 예상치를 넘어
Immatics NV earnings beat by €0.13, revenue topped estimates
Nuvation Bio Inc. (NUVB) Reports Q4 Loss, Beats Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
Immatics Stock: PRAME Leader’s Transition To Commercial Reality (NASDAQ:IMTX)
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Salesforce and Micron Tech among market cap stock movers on Friday
Micron, Salesforce among market cap stock movers on Friday
이매틱스, Leerink Partners 목표 주가 $17로 상향
Immatics stock price target raised to $17 from $16 at Leerink Partners
Iovance Biotherapeutics: Several Positives, But Competition Still Threatens (NASDAQ:IOVA)